Brainjo Raises €2M to Develop VR-Based ADHD Therapy for Children
Key Takeaways
- ▸VR technology is finding legitimate clinical applications in mental healthcare, moving beyond consumer entertainment toward prescription-based digital therapeutics
- ▸brainjo's cautious approach—complementary to existing care, clinical trials planned, 2028 approval target—suggests serious intent to navigate healthcare regulation rather than overpromise
- ▸The ADHD market presents a compelling opportunity for digital health solutions due to specialist scarcity, long waitlists, and parental demand for accessible treatment options
Summary
Regensburg-based startup brainjo has closed a €2 million seed round led by HTGF to develop prescription-oriented VR-based digital therapeutics targeting ADHD in children. The company is positioning its product as a complement to conventional psychotherapy rather than a replacement, combining virtual reality with brain-computer-interface technology to help children practice attention and impulse control at home. The first product is being developed in partnership with MEDICE, with a clinical study planned and market approval targeted for 2028.
Brainjo addresses a significant gap in mental healthcare where ADHD specialists are scarce, waitlists are long, and families struggle to access timely care. The startup's approach differs from broader health-tech trends by focusing on behavioral change through immersive therapy experiences rather than AI-powered diagnostic tools or wellness dashboards. By positioning VR as a structured therapeutic tool with clear clinical applications rather than a lifestyle gadget, brainjo aims to eventually secure insurance reimbursement and establish a sustainable model for digital mental health delivery.
- Focusing on behavioral practice through immersive experiences represents a more credible healthcare application than symptom interpretation or wellness dashboards
Editorial Opinion
Brainjo's €2M seed represents a refreshing counterpoint to health-tech hype: a startup pursuing narrow clinical outcomes through established therapeutic principles rather than betting on AI to disrupt psychiatry overnight. By treating VR as a behavioral practice tool rather than a complete care replacement, and committing to proper clinical trials with a realistic 2028 timeline, the company demonstrates the kind of rigor that makes digital health innovations actually credible. If they deliver, this could prove that VR's real killer app wasn't the metaverse—it was helping kids with ADHD do their homework.
